Avalo Therapeutics AVTX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Avalo Therapeutics (AVTX) reported accretion (amortization) of discounts and premiums, investments of $106K in Q1 2026.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to the carrying value of investment securities held by the company. It reflects the systematic recognition of interest income or expense resulting from the difference between the purchase price and the par value of debt instruments. Investors use this to understand the non-cash components of investment income that impact the company's reported financial performance.